Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lovenox Lawsuit May Be Omen For Biosimilar Battles

Executive Summary

Sanofi-Aventis' suit against FDA seeking to overturn its approval of generic Lovenox (enoxaparin) is a harbinger of what the agency will face once it approves follow-on biologics

You may also be interested in...



U.S. Congressional Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not

A U.S. House of Representatives Energy and Commerce Committee investigation into who caused contamination of heparin supplies in 2007 and 2008, how it was done, and U.S. FDA's handling of the crisis, could revive interest in legislation designed to strengthen FDA's oversight of drugs and other medical products entering the U.S. from overseas

House Investigation Of Tainted Heparin Could Highlight Need For Import Safety Legislation - Or Not

Energy and Commerce Republicans seek to determine who contaminated heparin supplies in 2008, how they did it, and why FDA has failed to answer those questions as the panel begins oversight of the agency.

Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA

Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).

Related Content

Topics

UsernamePublicRestriction

Register

PS052482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel